<DOC>
	<DOCNO>NCT01270503</DOCNO>
	<brief_summary>This aim study ass post-marketing safety single dose Menactra® vaccine intent support conversion monitor release initial registration Menactra® vaccine Philippines . Primary Objective : To describe serious adverse event occur within 30 day among participant receive one dose Menactra® vaccine .</brief_summary>
	<brief_title>Post-Marketing Safety Study Menactra® Healthy Children , Adolescents , Adults Philippines</brief_title>
	<detailed_description>Each study participant receive one dose Menactra® vaccine monitor safety 30 day post-vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<criteria>Aged 2 11 year age day inclusion ( Group 1 ) Aged 12 17 year age day inclusion ( Group 2 ) Aged 18 55 year age day inclusion ( Group 3 ) Provision inform consent form sign parent ( ) legal representative ( Group 1 ) Provision assent form sign subject informed consent form sign parent ( ) legal representative ( Group 2 ) Provision inform consent form sign subject ( Group 3 ) If subject ( Group 3 ) subject 's parent legally accept representative ( Group 1 2 ) illiterate , independent witness require sign consent form Subject parent/legally acceptable representative ( applicable ) able attend schedule visit comply trial procedure For woman childbearing potential , sexually active , use medically acceptable effective method contraception least 4 week prior vaccination , least 4 week vaccination ( applicable female childbearing potential sexually active ) . For woman childbearing potential sexually active , know suspected pregnancy positive serum/urine pregnancy test ( applicable female childbearing potential sexually active ) Breastfeeding woman Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion , opinion Investigator Receipt vaccine 4 week precede trial vaccination Planned receipt vaccine present trial period Known personal maternal Human Immunodeficiency virus ( HIV ) , Hepatitis B antigen Hepatitis C seropositivity report subject/parent/guardian and/or base medical history History seizures Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular injection Personal family history GuillainBarré Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>Menactra®</keyword>
</DOC>